The Agili-C implant supposts bone remodeling and cartilage regeneration, and it recieved FDA breakthrough designation in 2020, according to a news release. It is designed for International Cartilage Repair Society grade III or above knee-joint surface lesions.
“Agili-C is a technology I and others in the surgical community have been watching and waiting on for over 10 years,” Dr. Zaslav said in the release. “It is a novel implant supported by 4-years of data and counting from the multinational, randomized and controlled IDE clinical trial. Agili-C offers a cost efficient, off-the-shelf implant to fill an unmet need in my clinical practice.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
